Muscle & Brawn 2.0 is live! New Tools, Voice Reader, Compound Index, Features and more on the way. Want to explore what’s new → Click Here
Independent & reader-supported — every article medically reviewed

Peptides / GH and IGF

155 In the index

AOD-9604 AOD

A modified fragment of growth hormone marketed for fat loss without growth hormone's other effects. The company that developed it ran human trials, and those trials found it caused no more fat loss than a placebo, despite it remaining popular in research-chemical circles.

Also known as Anti-obesity drug 9604, AOD 9604, RefChem:113278, Tyr-somatostatin (177-191), Somatostatin (177-191), Tyr-, Somatostatin (177-191), tyrosyl-, 7UP768IP4M, orb1910051, EX-A4625

Effects Lose fat
Routes Subcutaneous
Legal status Research chemical
WADA Banned at all times

Molecular Structure of C78H123N23O23S2

Drag to rotate · scroll to zoom

  • Carbon
  • Hydrogen
  • Nitrogen
  • Oxygen
  • Sulfur

Chemistry

Formula
C78H123N23O23S2
Molar mass
1815.1
CAS
221231-10-3
PubChem CID
71300630
IUPAC name
(2S)-2-[[2-[[(4R,7S,13S,16S,19S,22S,25R)-25-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]-22-(3-carbamimidamidopropyl)-13-(2-carboxyethyl)-7,19-bis(hydroxymethyl)-6,9,12,15,18,21,24-heptaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacosane-4-carbonyl]amino]acetyl]amino]-3-phenylpropanoic acid
InChIKey
GVIYUKXRXPXMQM-BPXGDYAESA-N

Reported dosing

User-reported

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 300 mcg
Reported range 250-500 mcg/day
Route Subcutaneous injection
Frequency Once daily
Duration Ongoing/cyclical (unregulated use)

Failed to show meaningful weight-loss benefit over placebo in its own Phase IIb trial; not FDA-approved. Current sales are as a 'research chemical' only.

Where this comes from Phase IIb clinical trial (Metabolic Pharmaceuticals); user-reported dosing

There is no approved human dosing for this compound. The figures above are what users and vendors report, not what has been established as safe or effective. Treat them as a record of what is done, not as guidance.